GTCR to Acquire Surmodics for $43.00 per Share; Equity Value Approximately $627M

GTCR, a leading private equity firm, will acquire Surmodics, a Minnesota-based medical device and in vitro diagnostic technologies company, for $43.00 per share in cash, implying an approximate equity value of $627 million. The transaction, unanimously approved by Surmodics' board, is expected to close in the second half of 2024 and will take Surmodics private following customary regulatory and shareholder approvals.